These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 27654579)

  • 1. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?
    Platzbecker U; Germing U
    Leukemia; 2013 Sep; 27(9):1813-9. PubMed ID: 23644421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
    Zeidan AM; Kharfan-Dabaja MA; Komrokji RS
    Curr Opin Hematol; 2014 Mar; 21(2):123-30. PubMed ID: 24335709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
    Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
    Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
    Chandhok NS; Lewis R; Prebet T
    Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of higher-risk myelodysplastic syndrome.
    Garcia-Manero G
    Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making the most of hypomethylating agents in myelodysplastic syndrome.
    Bhatt G; Blum W
    Curr Opin Hematol; 2017 Mar; 24(2):79-88. PubMed ID: 28099273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
    Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
    Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing hypomethylating agents in myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
    Zeidan AM; Klink AJ; McGuire M; Feinberg B
    Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.
    Cherian MA; Tibes R; Gao F; Fletcher T; Fiala M; Uy GL; Westervelt P; Jacoby MA; Cashen AF; Stockerl-Goldstein K; DiPersio JF; Vij R
    Leuk Lymphoma; 2016 Nov; 57(11):2535-40. PubMed ID: 27122296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.